Most Influential NEJM Papers (2022-02)
The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals as well as the oldest continuously published one. Paper Digest Team analyze all papers published on NEJM in the past years, and presents the 10 most influential papers for each year (based on when the paper became available online). This ranking list is automatically constructed based upon citations from both research papers and granted patents, and will be frequently updated to reflect the most recent changes. To find the most influential papers from other conferences/journals, visit Best Paper Digest page. Note: the most influential papers may or may not include the papers that won the best paper awards. (Last updated on: 2022-02-05)
If you do not want to miss any interesting academic paper, you are welcome to sign up our free daily paper digest service to get updates on new papers published in your area every day. To search for papers with highlights, related papers, patents, grants, experts and organizations, please visit our search console. You are also welcome to follow us on Twitter and Linkedin to get updated with new conference digests.
Paper Digest Team
team@paperdigest.org
TABLE 1: Most Influential NEJM Papers (2022-02)
| Year | Rank | Paper | Author(s) |
|---|---|---|---|
| 2021 | 1 | BNT162b2 MRNA Covid-19 Vaccine in A Nationwide Mass Vaccination Setting IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse … |
NOA DAGAN et. al. |
| 2021 | 2 | Effectiveness of Covid-19 Vaccines Against The B.1.617.2 (Delta) Variant IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a … |
JAMIE LOPEZ BERNAL et. al. |
| 2021 | 3 | Thrombotic Thrombocytopenia After ChAdOx1 NCov-19 Vaccination IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of … |
ANDREAS GREINACHER et. al. |
| 2021 | 4 | Diffuse Large B-Cell Lymphoma IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Raynell Lang; M John Gill; |
| 2021 | 5 | Efficacy of The ChAdOx1 NCoV-19 Covid-19 Vaccine Against The B.1.351 Variant IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is … |
SHABIR A MADHI et. al. |
| 2021 | 6 | Thrombosis and Thrombocytopenia After ChAdOx1 NCoV-19 Vaccination IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector … |
NINA H SCHULTZ et. al. |
| 2021 | 7 | Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. We evaluated tocilizumab and sarilumab in an … |
ANTHONY C GORDON et. al. |
| 2021 | 8 | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine Against Covid-19 IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) … |
JERALD SADOFF et. al. |
| 2021 | 9 | Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been … |
ROMINA LIBSTER et. al. |
| 2021 | 10 | Effectiveness of The BNT162b2 Covid-19 Vaccine Against The B.1.1.7 and B.1.351 Variants IF:6 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Laith J Abu-Raddad; Hiam Chemaitelly; Adeel A Butt; AA; |
| 2020 | 1 | Clinical Characteristics of Coronavirus Disease 2019 in China IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of … |
WEI-JIE GUAN et. al. |
| 2020 | 2 | A Novel Coronavirus From Patients With Pneumonia In China, 2019 IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was … |
NA ZHU et. al. |
| 2020 | 3 | Aerosol and Surface Stability of SARS-CoV-2 As Compared with SARS-CoV-1 IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
NEELTJE VAN DOREMALEN et. al. |
| 2020 | 4 | First Case Of 2019 Novel Coronavirus In The United States IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV … |
MICHELLE L HOLSHUE et. al. |
| 2020 | 5 | Safety and Efficacy of The BNT162b2 MRNA Covid-19 Vaccine IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a … |
FERNANDO P POLACK et. al. |
| 2020 | 6 | SARS-CoV-2 Viral Load In Upper Respiratory Specimens Of Infected Patients IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
LIRONG ZOU et. al. |
| 2020 | 7 | Transmission Of 2019-nCoV Infection From An Asymptomatic Contact In Germany IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
CAMILLA ROTHE et. al. |
| 2020 | 8 | Efficacy and Safety of The MRNA-1273 SARS-CoV-2 Vaccine IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid … |
LINDSEY R BADEN et. al. |
| 2020 | 9 | Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the … |
MAXIMILIAN ACKERMANN et. al. |
| 2020 | 10 | Compassionate Use of Remdesivir for Patients with Severe Covid-19 IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis … |
JONATHAN GREIN et. al. |
| 2019 | 1 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of … |
VLADO PERKOVIC et. al. |
| 2019 | 2 | Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through … |
JOHN J V MCMURRAY et. al. |
| 2019 | 3 | Five-Year Survival With Combined Nivolumab And Ipilimumab In Advanced Melanoma IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. … |
JAMES LARKIN et. al. |
| 2019 | 4 | A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the … |
SABUE MULANGU et. al. |
| 2019 | 5 | Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab … |
MATTHEW D HELLMANN et. al. |
| 2019 | 6 | Efficacy And Safety Of Low-Dose Colchicine After Myocardial Infarction IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory … |
JEAN-CLAUDE TARDIF et. al. |
| 2019 | 7 | Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: BACKGROUND Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase … |
TALIA GOLAN et. al. |
| 2019 | 8 | Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients … |
SCOTT D SOLOMON et. al. |
| 2019 | 9 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both … |
SURESH S RAMALINGAM et. al. |
| 2019 | 10 | Hepatocellular Carcinoma IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Augusto Villanueva; |
| 2018 | 1 | Thrombectomy For Stroke At 6 To 16 Hours With Selection By Perfusion Imaging IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Thrombectomy is currently recommended for eligible patients with stroke who are treated within 6 hours after the onset of symptoms. We conducted a multicenter, randomized, … |
GREGORY W ALBERS et. al. |
| 2018 | 2 | Nivolumab Plus Ipilimumab in Lung Cancer with A High Tumor Mutational Burden IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a … |
MATTHEW D HELLMANN et. al. |
| 2018 | 3 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is … |
STEPHEN D WIVIOTT et. al. |
| 2018 | 4 | Overall Survival With Durvalumab After Chemoradiotherapy In Stage III NSCLC IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, … |
SCOTT J ANTONIA et. al. |
| 2018 | 5 | Cardiovascular Risk Reduction With Icosapent Ethyl For Hypertriglyceridemia IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride … |
DEEPAK L BHATT et. al. |
| 2018 | 6 | Patisiran, An RNAi Therapeutic, For Hereditary Transthyretin Amyloidosis IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin. In this phase 3 trial, we randomly assigned patients … |
DAVID ADAMS et. al. |
| 2018 | 7 | Maintenance Olaparib In Patients With Newly Diagnosed Advanced Ovarian Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the … |
KATHLEEN MOORE et. al. |
| 2018 | 8 | Cabozantinib In Patients With Advanced And Progressing Hepatocellular Carcinoma IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular … |
GHASSAN K ABOU-ALFA et. al. |
| 2018 | 9 | FOLFIRINOX Or Gemcitabine As Adjuvant Therapy for Pancreatic Cancer IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival … |
THIERRY CONROY et. al. |
| 2018 | 10 | Extracorporeal Membrane Oxygenation For Severe Acute Respiratory Distress Syndrome IF:7 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The efficacy of venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome (ARDS) remains controversial. In an international … |
ALAIN COMBES et. al. |
| 2017 | 1 | Antiinflammatory Therapy With Canakinumab For Atherosclerotic Disease IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of … |
PAUL M RIDKER et. al. |
| 2017 | 2 | Health Effects of Overweight and Obesity in 195 Countries Over 25 Years IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Although the rising pandemic of obesity has received major attention in many countries, the effects of this attention on trends and the disease burden of obesity remain uncertain. … |
ASHKAN AFSHIN et. al. |
| 2017 | 3 | Evolocumab And Clinical Outcomes In Patients With Cardiovascular Disease IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by … |
MARC S SABATINE et. al. |
| 2017 | 4 | Canagliflozin And Cardiovascular And Renal Events In Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We … |
BRUCE NEAL et. al. |
| 2017 | 5 | Overall Survival With Combined Nivolumab And Ipilimumab In Advanced Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients … |
JEDD D WOLCHOK et. al. |
| 2017 | 6 | Thrombectomy 6 To 24 Hours After Stroke With A Mismatch Between Deficit And Infarct IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is … |
RAUL G NOGUEIRA et. al. |
| 2017 | 7 | Tumor Mutational Burden And Response Rate To PD-1 Inhibition IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee; |
| 2017 | 8 | Rivaroxaban With Or Without Aspirin In Stable Cardiovascular Disease IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. In this double-blind … |
JOHN W EIKELBOOM et. al. |
| 2017 | 9 | Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III Or IV Melanoma IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved … |
JEFFREY WEBER et. al. |
| 2017 | 10 | Midostaurin Plus Chemotherapy For Acute Myeloid Leukemia With A FLT3 Mutation IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin – an oral … |
RICHARD M STONE et. al. |
| 2016 | 1 | Pembrolizumab Versus Chemotherapy For PD-L1-Positive Non-Small-Cell Lung Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased … |
MARTIN RECK et. al. |
| 2016 | 2 | Transcatheter Or Surgical Aortic-Valve Replacement In Intermediate-Risk Patients IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical … |
MARTIN B LEON et. al. |
| 2016 | 3 | A Randomized Trial Of Intensive Versus Standard Blood-Pressure Control IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Jackson T Wright; Paul K Whelton; David M Reboussin; |
| 2016 | 4 | Semaglutide And Cardiovascular Outcomes In Patients With Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular … |
STEVEN P MARSO et. al. |
| 2016 | 5 | Liraglutide And Cardiovascular Outcomes In Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
John B Buse; JB; |
| 2016 | 6 | Zika Virus Associated With Microcephaly IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: A widespread epidemic of Zika virus (ZIKV) infection was reported in 2015 in South and Central America and the Caribbean. A major concern associated with this infection is the … |
JERNEJ MLAKAR et. al. |
| 2016 | 7 | Genomic Classification And Prognosis In Acute Myeloid Leukemia IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines … |
ELLI PAPAEMMANUIL et. al. |
| 2016 | 8 | Empagliflozin And Progression Of Kidney Disease In Type 2 Diabetes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Christoph Wanner; Silvio E Inzucchi; Bernard Zinman; |
| 2016 | 9 | Mutations Associated With Acquired Resistance To PD-1 Blockade In Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted … |
JESSE M ZARETSKY et. al. |
| 2016 | 10 | Zika Virus IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
Lyle R Petersen; Denise J Jamieson; Ann M Powers; Margaret A Honein; |
| 2015 | 1 | Nivolumab Versus Docetaxel In Advanced Nonsquamous Non-Small-Cell Lung Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. In this … |
HOSSEIN BORGHAEI et. al. |
| 2015 | 2 | Nivolumab Versus Docetaxel In Advanced Squamous-Cell Non-Small-Cell Lung Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This … |
JULIE BRAHMER et. al. |
| 2015 | 3 | Empagliflozin, Cardiovascular Outcomes, And Mortality In Type 2 Diabetes IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 … |
BERNARD ZINMAN et. al. |
| 2015 | 4 | Pembrolizumab Versus Ipilimumab In Advanced Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune … |
CAROLINE ROBERT et. al. |
| 2015 | 5 | Nivolumab Versus Everolimus In Advanced Renal-Cell Carcinoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with … |
ROBERT J MOTZER et. al. |
| 2015 | 6 | Endovascular Therapy For Ischemic Stroke With Perfusion-imaging Selection IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Trials of endovascular therapy for ischemic stroke have produced variable results. We conducted this study to test whether more advanced imaging selection, recently developed … |
BRUCE C V CAMPBELL et. al. |
| 2015 | 7 | Combined Nivolumab And Ipilimumab Or Monotherapy In Untreated Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have … |
JAMES LARKIN et. al. |
| 2015 | 8 | Pembrolizumab For The Treatment Of Non-small-cell Lung Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 … |
EDWARD B GARON et. al. |
| 2015 | 9 | A New Initiative On Precision Medicine IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: President Obama has announced a research initiative that aims to accelerate progress toward a new era of precision medicine, with a near-term focus on cancers and a longer-term … |
Francis S Collins; Harold Varmus; |
| 2015 | 10 | Randomized Assessment Of Rapid Endovascular Treatment Of Ischemic Stroke IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence … |
MAYANK GOYAL et. al. |
| 2014 | 1 | A Randomized Trial Of Intraarterial Treatment For Acute Ischemic Stroke IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency revascularization. However, … |
OLVERT A BERKHEMER et. al. |
| 2014 | 2 | Nivolumab In Previously Untreated Melanoma Without BRAF Mutation IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of … |
CAROLINE ROBERT et. al. |
| 2014 | 3 | Angiotensin-neprilysin Inhibition Versus Enalapril in Heart Failure IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril … |
JOHN J V MCMURRAY et. al. |
| 2014 | 4 | Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may … |
SHANNON L MAUDE et. al. |
| 2014 | 5 | PD-1 Blockade With Nivolumab In Relapsed Or Refractory Hodgkin’s Lymphoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin’s lymphoma, alterations in … |
STEPHEN M ANSELL et. al. |
| 2014 | 6 | Genetic Basis For Clinical Response To CTLA-4 Blockade In Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against … |
ALEXANDRA SNYDER et. al. |
| 2014 | 7 | Multistate Point-prevalence Survey of Health Care-associated Infections IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Currently, no single U.S. surveillance system can provide estimates of the burden of all types of health care-associated infections across acute care patient populations. We … |
SHELLEY S MAGILL et. al. |
| 2014 | 8 | Age-related Clonal Hematopoiesis Associated With Adverse Outcomes IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The incidence of hematologic cancers increases with age. These cancers are associated with recurrent somatic mutations in specific genes. We hypothesized that such mutations would … |
SIDDHARTHA JAISWAL et. al. |
| 2014 | 9 | First-line Crizotinib Versus Chemotherapy In ALK-positive Lung Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is … |
BENJAMIN J SOLOMON et. al. |
| 2014 | 10 | Transcatheter Aortic-valve Replacement With A Self-expanding Prosthesis IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details |
David H Adams; Jeffrey J Popma; Michael J Reardon; |
| 2013 | 1 | Increased Survival in Pancreatic Cancer with Nab-paclitaxel Plus Gemcitabine IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We … |
DANIEL D VON HOFF et. al. |
| 2013 | 2 | Nivolumab Plus Ipilimumab in Advanced Melanoma IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the … |
JEDD D WOLCHOK et. al. |
| 2013 | 3 | Edoxaban Versus Warfarin in Patients with Atrial Fibrillation IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial … |
ROBERT P GIUGLIANO et. al. |
| 2013 | 4 | Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not … |
TIMOTHY J LEY et. al. |
| 2013 | 5 | Safety and Tumor Responses with Lambrolizumab (anti-PD-1) in Melanoma IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody … |
OMID HAMID et. al. |
| 2013 | 6 | Crizotinib Versus Chemotherapy In Advanced ALK-positive Lung Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral … |
ALICE T SHAW et. al. |
| 2013 | 7 | Duodenal Infusion Of Donor Feces For Recurrent Clostridium Difficile IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in … |
ELS VAN NOOD et. al. |
| 2013 | 8 | Saxagliptin And Cardiovascular Outcomes In Patients With Type 2 Diabetes Mellitus IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. We randomly … |
BENJAMIN M SCIRICA et. al. |
| 2013 | 9 | Chimeric Antigen Receptor-modified T Cells for Acute Lymphoid Leukemia IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established … |
STEPHAN A GRUPP et. al. |
| 2013 | 10 | Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart … |
SARAH C DARBY et. al. |
| 2012 | 1 | Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an … |
SUZANNE L TOPALIAN et. al. |
| 2012 | 2 | Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host’s immune … |
JULIE R BRAHMER et. al. |
| 2012 | 3 | Intratumor Heterogeneity and Branched Evolution Revealed By Multiregion Sequencing IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. To examine … |
MARCO GERLINGER et. al. |
| 2012 | 4 | Isolation Of A Novel Coronavirus From A Man With Pneumonia In Saudi Arabia IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: A previously unknown coronavirus was isolated from the sputum of a 60-year-old man who presented with acute pneumonia and subsequent renal failure with a fatal outcome in Saudi … |
Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier; |
| 2012 | 5 | Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether … |
HOWARD I SCHER et. al. |
| 2012 | 6 | Preoperative Chemoradiotherapy For Esophageal Or Junctional Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy … |
P VAN HAGEN et. al. |
| 2012 | 7 | Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. We conducted a … |
JARED M BAETEN et. al. |
| 2012 | 8 | Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The order and magnitude of pathologic processes in Alzheimer’s disease are not well understood, partly because the disease develops over many years. Autosomal dominant Alzheimer’s … |
RANDALL J BATEMAN et. al. |
| 2012 | 9 | Trastuzumab Emtansine for HER2-positive Advanced Breast Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the … |
SUNIL VERMA et. al. |
| 2012 | 10 | Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Estimates of glomerular filtration rate (GFR) that are based on serum creatinine are routinely used; however, they are imprecise, potentially leading to the overdiagnosis of … |
LESLEY A INKER et. al. |
| 2011 | 1 | Rivaroxaban Versus Warfarin In Nonvalvular Atrial Fibrillation IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa … |
MANESH R PATEL et. al. |
| 2011 | 2 | Reduced Lung-cancer Mortality With Low-dose Computed Tomographic Screening IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical … |
DENISE R ABERLE et. al. |
| 2011 | 3 | Apixaban Versus Warfarin In Patients With Atrial Fibrillation IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa … |
CHRISTOPHER B GRANGER et. al. |
| 2011 | 4 | Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF … |
PAUL B CHAPMAN et. al. |
| 2011 | 5 | Prevention of HIV-1 Infection with Early Antiretroviral Therapy IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. In nine countries, we … |
MYRON S COHEN et. al. |
| 2011 | 6 | FOLFIRINOX Versus Gemcitabine For Metastatic Pancreatic Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with … |
THIERRY CONROY et. al. |
| 2011 | 7 | Ipilimumab Plus Dacarbazine For Previously Untreated Metastatic Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with … |
CAROLINE ROBERT et. al. |
| 2011 | 8 | Transcatheter Versus Surgical Aortic-valve Replacement In High-risk Patients IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The use of transcatheter aortic-valve replacement has been shown to reduce mortality among high-risk patients with aortic stenosis who are not candidates for surgical replacement. … |
CRAIG R SMITH et. al. |
| 2011 | 9 | Abiraterone And Increased Survival In Metastatic Prostate Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen … |
JOHANN S DE BONO et. al. |
| 2011 | 10 | Chimeric Antigen Receptor-modified T Cells In Chronic Lymphoid Leukemia IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells … |
David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June; |
| 2010 | 1 | Improved Survival With Ipilimumab In Patients With Metastatic Melanoma IF:10 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab–which blocks cytotoxic … |
F STEPHEN HODI et. al. |
| 2010 | 2 | Transcatheter Aortic-valve Implantation For Aortic Stenosis In Patients Who Cannot Undergo Surgery IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Many patients with severe aortic stenosis and coexisting conditions are not candidates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve … |
MARTIN B LEON et. al. |
| 2010 | 3 | Sipuleucel-T Immunotherapy For Castration-resistant Prostate Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate … |
PHILIP W KANTOFF et. al. |
| 2010 | 4 | Early Palliative Care For Patients With Metastatic Non-small-cell Lung Cancer IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing … |
JENNIFER S TEMEL et. al. |
| 2010 | 5 | Human Papillomavirus And Survival Of Patients With Oropharyngeal Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status … |
K KIAN ANG et. al. |
| 2010 | 6 | Gefitinib Or Chemotherapy For Non-small-cell Lung Cancer With Mutated EGFR IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but … |
MAKOTO MAEMONDO et. al. |
| 2010 | 7 | Inhibition Of Mutated, Activated BRAF In Metastatic Melanoma IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test … |
KEITH T FLAHERTY et. al. |
| 2010 | 8 | Preexposure Chemoprophylaxis For HIV Prevention In Men Who Have Sex With Men IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. We randomly assigned 2499 … |
ROBERT M GRANT et. al. |
| 2010 | 9 | Anaplastic Lymphoma Kinase Inhibition In Non-small-cell Lung Cancer IF:9 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We … |
EUNICE L KWAK et. al. |
| 2010 | 10 | Effects Of Intensive Blood-pressure Control In Type 2 Diabetes Mellitus IF:8 Related Papers Related Patents Related Grants Related Orgs Related Experts Details Abstract: There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We … |
WILLIAM C CUSHMAN et. al. |